Schrodinger (SDGR) Stock
Software platform for drug discovery and materials research. Here's the price, business snapshot, and what's worth knowing about Schrodinger in October 2026.
Schrödinger, Inc. (SDGR) provides computational chemistry and materials-modelling software used across drug discovery and materials research. Investors should know it sells a combination of software licences, cloud subscriptions, and collaborative research services to pharmaceutical, biotech and materials customers. The firm’s value proposition centres on physics-based simulation to help researchers identify and optimise molecules more efficiently, which can shorten discovery timelines and reduce experimental cost. Key drivers include adoption of its platform, growth in recurring revenue, and partnerships with larger drug developers. Risks include customer concentration, long sales cycles in life sciences, competition from other modelling tools and shifts in R&D spending. As a smaller-cap technology-driven company (market cap ~US$1.54bn), its shares can be volatile. This summary is educational and not personal investment advice — investors should consider their goals, seek diverse information, and be aware that past trends don’t guarantee future performance.
Schrodinger (SDGR) Stock Forecast
Analyst price target, next 12 months
$27.87
-8.1% vs today's $30.31
Price range over the last 12 months
Close to its 12-month high
Analysts covering Schrodinger have a consensus 12-month target of $27.87, below the current price of $30.31.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Schrodinger's stock with a target price of $27.87, indicating potential growth.
Financial Health
Schrodinger Inc is performing well with solid revenue, strong cash flow, and good profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform-driven growth
Recurring licences and cloud subscriptions can underpin steady revenue expansion, though adoption rates and customer spend can vary over time.
Technology edge
Physics-based modelling can offer scientific differentiation and efficiency benefits, but competition and continuous R&D investment are ongoing challenges.
Partner ecosystem
Collaborations with pharma and academic institutions broaden reach and credibility, yet outcomes depend on successful integration and customer budgets.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
